Thomas (TJ) FitzGerald

Dr. Thomas (TJ) FitzGerald

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJeff Michalski
Jeff Michalski
AJAnna J. Janss
Anna J. Janss
LVL. Gilbert Vezina
L. Gilbert Vezina
KSKyle S. Smith
Kyle S. Smith
CBCatherine A. Billups
Catherine A. Billups
PNPaul A. Northcott
Paul A. Northcott
PURPOSE: Children with average-risk medulloblastoma (MB) experience survival rates of ≥ 80% at the expense of adverse consequences of treatment. Efforts to mitigate these effects include deintensification of craniospinal irradiation (CSI) dose and volume. METHODS: ACNS0331 (ClinicalTrials.gov identifier: NCT00085735 ) randomly assigned patients age 3-21 years with average-risk MB to receive posterior fossa radiation therapy (PFRT) or involved field radiation therapy (IFRT) following CSI. Young children (3-7 years) were also randomly assigned to receive standard-dose CSI (SDCSI; 23.4 Gy) or low-dose CSI (LDCSI; 18 Gy). Post hoc molecular classification and mutational analysis contextualized outcomes according to known biologic subgroups (Wingless, Sonic Hedgehog, group 3, and group 4) and genetic biomarkers. Neurocognitive changes and ototoxicity were monitored over time. RESULTS: Five hundred forty-nine patients were enrolled on study, of which 464 were eligible and evaluable to compare PFRT versus IFRT and 226 for SDCSI versus LDCSI. The five-year event-free survival (EFS) was 82.5% (95% CI, 77.2 to 87.8) and 80.5% (95% CI, 75.2 to 85.8) for the IFRT and PFRT regimens, respectively, and 71.4% (95% CI, 62.8 to 80) and 82.9% (95% CI, 75.6 to 90.2) for the LDCSI and SDCSI regimens, respectively. IFRT was not inferior to PFRT (hazard ratio, 0.97; 94% upper CI, 1.32). LDCSI was inferior to SDCSI (hazard ratio, 1.67%; 80% upper CI, 2.10). Improved EFS was observed in patients with Sonic Hedgehog MB who were randomly assigned to the IFRT arm ( P = .018). Patients with group 4 MB receiving LDCSI exhibited inferior EFS ( P = .047). Children receiving SDCSI exhibited greater late declines in IQ (estimate = 5.87; P = .021). CONCLUSION: Reducing the radiation boost volume in average-risk MB is safe and does not compromise survival. Reducing CSI dose in young children with average-risk MB results in inferior outcomes, possibly in a subgroup-dependent manner, but is associated with better neurocognitive outcome. Molecularly informed patient selection warrants further exploration for children with MB to be considered for late-effect sparing approaches.

1 February 2019 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
TWTao Wang
Tao Wang
JHJiayi Huang
Jiayi Huang
MVMai Vue
Mai Vue
MAMichael Rami Alavian
Michael Rami Alavian
HGHira Lal Goel
Hira Lal Goel
TFThomas (TJ) FitzGerald
Thomas (TJ) FitzGerald
The αvβ3 integrin is involved in various physiologic and pathologic processes such as wound healing, angiogenesis, tumor growth, and metastasis. The impact of αvβ3 integrin on the radiosensitivity of prostate cancer cells and the molecular mechanism controlling cell survival in response to ionizing radiation (IR) was investigated. Both LNCaP cells stably transfected with αvβ3 integrin and PC-3 cells that contain endogenous β3 integrin were used. This study demonstrated that αvβ3 integrin increases survival of αvβ3-LNCaP cells upon IR while small hairpin RNA (shRNA)-mediated knockdown of αvβ3 integrin in PC-3 cells sensitizes to radiation. Expression of αvβ3 integrin in LNCaP cells also enhances anchorage-independent cell growth while knockdown of αvβ3 integrin in PC-3 cells inhibits anchorage-independent cell growth. The αvβ3 antagonist, cRGD, significantly increases radiosensitivity in both αvβ3-LNCaP and PC-3 cells. Moreover, αvβ3 integrin prevents radiation-induced downregulation of survivin. Inhibition of survivin expression by siRNA or shRNA enhances IR-induced inhibition of anchorage-independent cell growth. Overexpression of wild-type survivin in PC-3 cells treated with αvβ3 integrin shRNA increases survival of cells upon IR. These findings reveal that αvβ3 integrin promotes radioresistance and regulates survivin levels in response to IR. Implications: Future translational research on targeting αvβ3 integrin and survivin may reveal novel approaches as an adjunct to radiotherapy for patients with prostate cancer.

1 April 2006 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RMRaymond Miralbell
Raymond Miralbell
TFThomas (TJ) FitzGerald
Thomas (TJ) FitzGerald
FLFran Laurie
Fran Laurie
SKSandy Kessel
Sandy Kessel
AGArvin Glicksman
Arvin Glicksman
NTNancy J. Tarbell
Nancy J. Tarbell

9 August 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CHChiaho Hua
Chiaho Hua
TVTamara Z. Vern‐Gross
Tamara Z. Vern‐Gross
CHClayton B. Hess
Clayton B. Hess
AOArthur J. Olch
Arthur J. Olch
PAParham Alaei
Parham Alaei
JKJohn A. Kalapurakal
John A. Kalapurakal

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TFThomas (TJ) FitzGerald
Thomas (TJ) FitzGerald
MBMaryann Bishop-Jodoin
Maryann Bishop-Jodoin
WBWalter R. Bosch
Walter R. Bosch
WCWalter J. Curran
Walter J. Curran
DFDavid S. Followill
David S. Followill
MUMarcia Urie
Marcia Urie
The National Cancer Institute clinical cooperative groups have been instrumental over the past 50 years in developing clinical trials and evidence-based process improvements for clinical oncology patient care. The cooperative groups are undergoing a transformation process as we further integrate molecular biology into personalized patient care and move to incorporate international partners in clinical trials. To support this vision, data acquisition and data management informatics tools must become both nimble and robust to support transformational research at an enterprise level. Information, including imaging, pathology, molecular biology, radiation oncology, surgery, systemic therapy, and patient outcome data needs to be integrated into the clinical trial charter using adaptive clinical trial mechanisms for design of the trial. This information needs to be made available to investigators using digital processes for real-time data analysis. Future clinical trials will need to be designed and completed in a timely manner facilitated by nimble informatics processes for data management. This paper discusses both past experience and future vision for clinical trials as we move to develop data management and quality assurance processes to meet the needs of the modern trial.

1 October 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AKAyush Kumar
Ayush Kumar
HGHira Lal Goel
Hira Lal Goel
CWChristi A Wisniewski
Christi A Wisniewski
TWTao Wang
Tao Wang
YGYansong Geng
Yansong Geng
AMArthur M. Mercurio
Arthur M. Mercurio
The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report that neuropilin-2 ( NRP2 ), a receptor for vascular endothelial growth factor ( VEGF ) that is enriched on subpopulations of TNBC cells with stem cell properties, is an effective therapeutic target for sensitizing TNBC to radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 ( NOS2 ) transcription by a mechanism dependent on Gli1. NRP2-expressing tumor cells serve as a hub to produce nitric oxide (NO), an autocrine and paracrine signaling metabolite, which promotes cysteine-nitrosylation of Kelch-like ECH-associated protein 1 ( KEAP1 ) and, consequently, nuclear factor erythroid 2-related factor 2–mediated ( NFE2L2 -mediated) transcription of antioxidant response genes. Inhibiting VEGF binding to NRP2, using a humanized mAb, results in NFE2L2 degradation via KEAP1, rendering cell lines and organoids vulnerable to irradiation. Importantly, treatment of patient-derived xenografts with the NRP2 mAb and radiation resulted in significant tumor necrosis and regression compared with radiation alone. Together, these findings reveal a targetable mechanism of radioresistance, and they support the use of NRP2 mAb as an effective radiosensitizer in TNBC.